Table 1. SPR analysis of monoclonal antibody binding to gp41 oligomers.
Immunogen (antibody) | Kon (1/Ms) | Koff (1/s) | KD (M) |
---|---|---|---|
FDA18 (2F5) | 4.73e3 | 8.34e-5 | 1.76e-8 |
FDA18 (4E10) | 3.9e3 | 8.24e-4 | 2.12e-7 |
FDA13 (2F5) | 1.35e5 | 6.69e-5 | 4.95e-10 |
FDA13 (4E10) | 1.17e3 | 6.11e-4 | 5.24e-7 |
FDA20 (2F5) | 9.67e3 | 9.21e-4 | 9.52e-8 |
FDA20 (4E10) | 1.18e3 | 1.04e-4 | 8.81e-8 |
FDA26 (2F5) | 2.31e4 | 9.03e-4 | 3.91e-8 |
FDA26 (4E10) | 1.44e4 | 1.95e-3 | 1.35e-7 |
FDA21 (2F5) | 2.26e4 | 4.2e-4 | 1.86e-8 |
FDA21 (4E10) | 1.87e4 | 4.57e-3 | 2.44e-7 |
FDAB4 (2F5) | 1.35e4 | 6.37e-4 | 4.73e-8 |
FDAB4 (4E10) | 7.47e3 | 2.33e-3 | 3.12e-7 |
FDA22 (2F5) | 2.19e4 | 3.56e-4 | 1.68e-8 |
FDA22 (4E10) | 6.54e3 | 5.28e-4 | 8.08e-8 |